Is Micron a Good Stock to Buy Now?
Like most of its peers in the semiconductor industry, Micron…
Sell
12
NVO Quote, Financials, Valuation and Earnings
Last price:
$58.45
Seasonality move
:
6.63%
Day range:
$62.40 - $64.41
52-week range:
$59.32 - $148.15
Dividend yield:
2.57%
P/E ratio:
19.15x
P/S ratio:
6.67x
P/B ratio:
13.94x
Volume:
6.3M
Avg. volume:
8M
1-year change:
-49.06%
Market cap:
$279.1B
Revenue:
$42.1B
EPS (TTM):
$3.28
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
NVO
Novo Nordisk AS
|
$11.9B | $0.89 | 24.96% | 34.19% | $106.21 |
|
AMGN
Amgen
|
$8B | $4.26 | 5.51% | 285.64% | $317.12 |
|
ASND
Ascendis Pharma AS
|
$106.3M | -$1.70 | 252.37% | -30.12% | $216.11 |
|
AZN
AstraZeneca PLC
|
$13.7B | $1.11 | 8.46% | 83.1% | $84.79 |
|
EVAX
Evaxion Biotech AS
|
$60K | -$0.71 | -59.42% | -91.42% | $13.25 |
|
ZLDPF
Zealand Pharma AS
|
$36.4M | -- | -5.47% | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
NVO
Novo Nordisk AS
|
$62.88 | $106.21 | $279.1B | 19.15x | $1.10 | 2.57% | 6.67x |
|
AMGN
Amgen
|
$282.64 | $317.12 | $151.8B | 37.44x | $2.38 | 3.23% | 4.57x |
|
ASND
Ascendis Pharma AS
|
$158.15 | $216.11 | $9.5B | -- | $0.00 | 0% | 23.36x |
|
AZN
AstraZeneca PLC
|
$67.05 | $84.79 | $207.9B | 29.73x | $1.05 | 2.31% | 3.87x |
|
EVAX
Evaxion Biotech AS
|
$1.31 | $13.25 | $8.3M | -- | $0.00 | 0% | 0.42x |
|
ZLDPF
Zealand Pharma AS
|
$66.12 | -- | $4.7B | -- | $0.00 | 0% | 484.29x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
NVO
Novo Nordisk AS
|
40.09% | 1.361 | 3.51% | 0.52x |
|
AMGN
Amgen
|
91.09% | 0.284 | 43.85% | 0.84x |
|
ASND
Ascendis Pharma AS
|
114.08% | 0.580 | 10.82% | 0.81x |
|
AZN
AstraZeneca PLC
|
41.27% | -0.160 | -- | 0.74x |
|
EVAX
Evaxion Biotech AS
|
-- | -1.937 | -- | 2.80x |
|
ZLDPF
Zealand Pharma AS
|
3.21% | 1.851 | 0.55% | 20.85x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
NVO
Novo Nordisk AS
|
$10.4B | $5.2B | 60.28% | 86.85% | 40.78% | -$786.4M |
|
AMGN
Amgen
|
$6B | $2.3B | 5.97% | 66.87% | 16.83% | $4.4B |
|
ASND
Ascendis Pharma AS
|
$170.4M | $408.3K | -69.61% | -880.05% | -24.36% | -$90.9M |
|
AZN
AstraZeneca PLC
|
$12.2B | $2B | 9.88% | 17.77% | 14.07% | $2B |
|
EVAX
Evaxion Biotech AS
|
-- | -$1.7M | -238.97% | -- | -54.59% | -- |
|
ZLDPF
Zealand Pharma AS
|
$1.2M | -$56.6M | -16.68% | -17.27% | -3128.75% | -$24.9M |
Novo Nordisk AS vs. Competitors
-
Which has Higher Returns NVO or AMGN?
Amgen has a net margin of 32.95% compared to Novo Nordisk AS's net margin of 6.9%. Novo Nordisk AS's return on equity of 86.85% beat Amgen's return on equity of 66.87%.
Company Gross Margin Earnings Per Share Invested Capital NVONovo Nordisk AS84.8% $0.91 $33.4B AMGNAmgen65.75% $1.16 $66B -
What do Analysts Say About NVO or AMGN?
Novo Nordisk AS has a consensus price target of $106.21, signalling upside risk potential of 68.91%. On the other hand Amgen has an analysts' consensus of $317.12 which suggests that it could grow by 12.2%. Given that Novo Nordisk AS has higher upside potential than Amgen, analysts believe Novo Nordisk AS is more attractive than Amgen.
Company Buy Ratings Hold Ratings Sell Ratings NVONovo Nordisk AS4 3 1 AMGNAmgen9 14 2 -
Is NVO or AMGN More Risky?
Novo Nordisk AS has a beta of 0.614, which suggesting that the stock is 38.645% less volatile than S&P 500. In comparison Amgen has a beta of 0.583, suggesting its less volatile than the S&P 500 by 41.682%.
-
Which is a Better Dividend Stock NVO or AMGN?
Novo Nordisk AS has a quarterly dividend of $1.10 per share corresponding to a yield of 2.57%. Amgen offers a yield of 3.23% to investors and pays a quarterly dividend of $2.38 per share. Novo Nordisk AS pays 43.71% of its earnings as a dividend. Amgen pays out 118.14% of its earnings as a dividend. Novo Nordisk AS's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Amgen's is not.
-
Which has Better Financial Ratios NVO or AMGN?
Novo Nordisk AS quarterly revenues are $12.2B, which are larger than Amgen quarterly revenues of $9.1B. Novo Nordisk AS's net income of $4B is higher than Amgen's net income of $627M. Notably, Novo Nordisk AS's price-to-earnings ratio is 19.15x while Amgen's PE ratio is 37.44x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novo Nordisk AS is 6.67x versus 4.57x for Amgen. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NVONovo Nordisk AS6.67x 19.15x $12.2B $4B AMGNAmgen4.57x 37.44x $9.1B $627M
-
Which has Higher Returns NVO or ASND?
Ascendis Pharma AS has a net margin of 32.95% compared to Novo Nordisk AS's net margin of -22.12%. Novo Nordisk AS's return on equity of 86.85% beat Ascendis Pharma AS's return on equity of -880.05%.
Company Gross Margin Earnings Per Share Invested Capital NVONovo Nordisk AS84.8% $0.91 $33.4B ASNDAscendis Pharma AS91.94% -$0.68 $781.4M -
What do Analysts Say About NVO or ASND?
Novo Nordisk AS has a consensus price target of $106.21, signalling upside risk potential of 68.91%. On the other hand Ascendis Pharma AS has an analysts' consensus of $216.11 which suggests that it could grow by 36.65%. Given that Novo Nordisk AS has higher upside potential than Ascendis Pharma AS, analysts believe Novo Nordisk AS is more attractive than Ascendis Pharma AS.
Company Buy Ratings Hold Ratings Sell Ratings NVONovo Nordisk AS4 3 1 ASNDAscendis Pharma AS12 1 0 -
Is NVO or ASND More Risky?
Novo Nordisk AS has a beta of 0.614, which suggesting that the stock is 38.645% less volatile than S&P 500. In comparison Ascendis Pharma AS has a beta of 0.540, suggesting its less volatile than the S&P 500 by 45.961%.
-
Which is a Better Dividend Stock NVO or ASND?
Novo Nordisk AS has a quarterly dividend of $1.10 per share corresponding to a yield of 2.57%. Ascendis Pharma AS offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Novo Nordisk AS pays 43.71% of its earnings as a dividend. Ascendis Pharma AS pays out -- of its earnings as a dividend. Novo Nordisk AS's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios NVO or ASND?
Novo Nordisk AS quarterly revenues are $12.2B, which are larger than Ascendis Pharma AS quarterly revenues of $185.4M. Novo Nordisk AS's net income of $4B is higher than Ascendis Pharma AS's net income of -$41M. Notably, Novo Nordisk AS's price-to-earnings ratio is 19.15x while Ascendis Pharma AS's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novo Nordisk AS is 6.67x versus 23.36x for Ascendis Pharma AS. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NVONovo Nordisk AS6.67x 19.15x $12.2B $4B ASNDAscendis Pharma AS23.36x -- $185.4M -$41M
-
Which has Higher Returns NVO or AZN?
AstraZeneca PLC has a net margin of 32.95% compared to Novo Nordisk AS's net margin of 10.07%. Novo Nordisk AS's return on equity of 86.85% beat AstraZeneca PLC's return on equity of 17.77%.
Company Gross Margin Earnings Per Share Invested Capital NVONovo Nordisk AS84.8% $0.91 $33.4B AZNAstraZeneca PLC81.7% $0.48 $69.5B -
What do Analysts Say About NVO or AZN?
Novo Nordisk AS has a consensus price target of $106.21, signalling upside risk potential of 68.91%. On the other hand AstraZeneca PLC has an analysts' consensus of $84.79 which suggests that it could grow by 26.46%. Given that Novo Nordisk AS has higher upside potential than AstraZeneca PLC, analysts believe Novo Nordisk AS is more attractive than AstraZeneca PLC.
Company Buy Ratings Hold Ratings Sell Ratings NVONovo Nordisk AS4 3 1 AZNAstraZeneca PLC6 1 0 -
Is NVO or AZN More Risky?
Novo Nordisk AS has a beta of 0.614, which suggesting that the stock is 38.645% less volatile than S&P 500. In comparison AstraZeneca PLC has a beta of 0.485, suggesting its less volatile than the S&P 500 by 51.487%.
-
Which is a Better Dividend Stock NVO or AZN?
Novo Nordisk AS has a quarterly dividend of $1.10 per share corresponding to a yield of 2.57%. AstraZeneca PLC offers a yield of 2.31% to investors and pays a quarterly dividend of $1.05 per share. Novo Nordisk AS pays 43.71% of its earnings as a dividend. AstraZeneca PLC pays out 65.8% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios NVO or AZN?
Novo Nordisk AS quarterly revenues are $12.2B, which are smaller than AstraZeneca PLC quarterly revenues of $14.9B. Novo Nordisk AS's net income of $4B is higher than AstraZeneca PLC's net income of $1.5B. Notably, Novo Nordisk AS's price-to-earnings ratio is 19.15x while AstraZeneca PLC's PE ratio is 29.73x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novo Nordisk AS is 6.67x versus 3.87x for AstraZeneca PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NVONovo Nordisk AS6.67x 19.15x $12.2B $4B AZNAstraZeneca PLC3.87x 29.73x $14.9B $1.5B
-
Which has Higher Returns NVO or EVAX?
Evaxion Biotech AS has a net margin of 32.95% compared to Novo Nordisk AS's net margin of -64.14%. Novo Nordisk AS's return on equity of 86.85% beat Evaxion Biotech AS's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital NVONovo Nordisk AS84.8% $0.91 $33.4B EVAXEvaxion Biotech AS-- -$0.40 $74K -
What do Analysts Say About NVO or EVAX?
Novo Nordisk AS has a consensus price target of $106.21, signalling upside risk potential of 68.91%. On the other hand Evaxion Biotech AS has an analysts' consensus of $13.25 which suggests that it could grow by 911.45%. Given that Evaxion Biotech AS has higher upside potential than Novo Nordisk AS, analysts believe Evaxion Biotech AS is more attractive than Novo Nordisk AS.
Company Buy Ratings Hold Ratings Sell Ratings NVONovo Nordisk AS4 3 1 EVAXEvaxion Biotech AS1 0 0 -
Is NVO or EVAX More Risky?
Novo Nordisk AS has a beta of 0.614, which suggesting that the stock is 38.645% less volatile than S&P 500. In comparison Evaxion Biotech AS has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock NVO or EVAX?
Novo Nordisk AS has a quarterly dividend of $1.10 per share corresponding to a yield of 2.57%. Evaxion Biotech AS offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Novo Nordisk AS pays 43.71% of its earnings as a dividend. Evaxion Biotech AS pays out -- of its earnings as a dividend. Novo Nordisk AS's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios NVO or EVAX?
Novo Nordisk AS quarterly revenues are $12.2B, which are larger than Evaxion Biotech AS quarterly revenues of $3M. Novo Nordisk AS's net income of $4B is higher than Evaxion Biotech AS's net income of -$1.9M. Notably, Novo Nordisk AS's price-to-earnings ratio is 19.15x while Evaxion Biotech AS's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novo Nordisk AS is 6.67x versus 0.42x for Evaxion Biotech AS. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NVONovo Nordisk AS6.67x 19.15x $12.2B $4B EVAXEvaxion Biotech AS0.42x -- $3M -$1.9M
-
Which has Higher Returns NVO or ZLDPF?
Zealand Pharma AS has a net margin of 32.95% compared to Novo Nordisk AS's net margin of -3213.72%. Novo Nordisk AS's return on equity of 86.85% beat Zealand Pharma AS's return on equity of -17.27%.
Company Gross Margin Earnings Per Share Invested Capital NVONovo Nordisk AS84.8% $0.91 $33.4B ZLDPFZealand Pharma AS95.5% -$0.59 $1.2B -
What do Analysts Say About NVO or ZLDPF?
Novo Nordisk AS has a consensus price target of $106.21, signalling upside risk potential of 68.91%. On the other hand Zealand Pharma AS has an analysts' consensus of -- which suggests that it could fall by -65.97%. Given that Novo Nordisk AS has higher upside potential than Zealand Pharma AS, analysts believe Novo Nordisk AS is more attractive than Zealand Pharma AS.
Company Buy Ratings Hold Ratings Sell Ratings NVONovo Nordisk AS4 3 1 ZLDPFZealand Pharma AS0 0 0 -
Is NVO or ZLDPF More Risky?
Novo Nordisk AS has a beta of 0.614, which suggesting that the stock is 38.645% less volatile than S&P 500. In comparison Zealand Pharma AS has a beta of 0.808, suggesting its less volatile than the S&P 500 by 19.219%.
-
Which is a Better Dividend Stock NVO or ZLDPF?
Novo Nordisk AS has a quarterly dividend of $1.10 per share corresponding to a yield of 2.57%. Zealand Pharma AS offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Novo Nordisk AS pays 43.71% of its earnings as a dividend. Zealand Pharma AS pays out -- of its earnings as a dividend. Novo Nordisk AS's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios NVO or ZLDPF?
Novo Nordisk AS quarterly revenues are $12.2B, which are larger than Zealand Pharma AS quarterly revenues of $1.3M. Novo Nordisk AS's net income of $4B is higher than Zealand Pharma AS's net income of -$41.6M. Notably, Novo Nordisk AS's price-to-earnings ratio is 19.15x while Zealand Pharma AS's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novo Nordisk AS is 6.67x versus 484.29x for Zealand Pharma AS. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NVONovo Nordisk AS6.67x 19.15x $12.2B $4B ZLDPFZealand Pharma AS484.29x -- $1.3M -$41.6M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Uber Finally on the Path to Consistent Profitability?
After posting massive losses quarter after quarter for years, Uber…
How High Will MSTY Go By 2030?
YieldMax’s MSTR Option Income Strategy ETF (MSTY) is a high-yield…
Stock Ideas
Sell
48
Is AAPL Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 32x
Sell
46
Is MSFT Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 31x
Sell
42
Is NVDA Stock a Buy?
Market Cap: $2.5T
P/E Ratio: 36x
Alerts
Buy
91
TORXF alert for Apr 17
Torex Gold Resources [TORXF] is down 1.58% over the past day.
Sell
25
BULZ alert for Apr 17
MicroSectors Solactive FANG & Innov 3X Levd ETN [BULZ] is down 2.15% over the past day.
Sell
44
VIST alert for Apr 17
Vista Energy SAB de CV [VIST] is up 7% over the past day.
